Pulse Biosciences Nanosecond PFA Cuts AFib Failure to 5%

Pulse Biosciences shared one-year clinical results for its nanosecond PFA system that could reshape the atrial fibrillation market. The European feasibility data shows a 5% clinical failure rate, far below the 25% repeat intervention rate seen with thermal and first-generation pulsed field ablation systems.

Electrophysiologist Dr. Vivek Reddy of Mount Sinai presented the data at the Heart Rhythm Society (HRS) 2026 Annual Meeting in Chicago. The reading is a key milestone as Pulse Biosciences moves toward regulatory approval.

What is nanosecond PFA

Pulsed field ablation (PFA) is the rising alternative to thermal cardiac ablation for AFib. Most PFA systems on the market run on microsecond pulses, measured in millionths of a second. Pulse Biosciences runs on nanosecond pulses, in billionths.

CEO Paul LaViolette argues this is not a small tweak. He said: "What's really important is the thousand-fold difference between the two. This is not a marginal gain, this is an exponential gain in pulse duration."

The shorter pulse lets the device run at higher voltage. The mix produces a unique mechanism of action, the company says. It can non-thermally clear cells while sparing nearby non-cellular tissue.

The 5% clinical failure data

At HRS 2026, Pulse Biosciences is showing one-year endpoint data from its European multicenter feasibility study. The endpoints: freedom from AFib for a year and freedom from atrial arrhythmias.

LaViolette put it bluntly: "If you ask most physicians about real-world performance, and this is true of thermal or first-generation PFA, one in four patients, 25%, will require repeat interventions one year later."

The data still needs confirmation in a pivotal trial. But LaViolette said no PFA technology to date has shown that degree of pulmonary vein isolation.

If the nanosecond PFA result holds up, it would mark a meaningful step down in repeat ablation rates, a long-standing pain point in AFib care.

A compliant catheter built for the left atrium

Pulse Biosciences is also using HRS 2026 to show its compliant catheter design through a live case. LaViolette argues catheter compliance matters for two reasons.

LaViolette said: "Compliance matters a lot for two reasons. One, ease of maneuvering the catheter around the left atrium and into the veins is improved with a more compliant catheter."

If the catheter is too rigid, electrodes can float off the tissue. That weakens energy delivery. A compliant design keeps electrodes in firm contact, which the company says supports a broader ablation footprint.

How nanosecond PFA stacks up against rivals

The PFA market is now crowded. Boston Scientific's FARAPULSE, Medtronic's PulseSelect, and Johnson & Johnson's VARIPULSE all run on microsecond pulses and are already in clinical use.

LaViolette rejects the fast-follower label. He frames nanosecond PFA as a new energy generation, not an iteration.

He pointed to recent share shifts in the AFib catheter market. Platforms with easier workflow have moved share fast, even without big differences in long-term outcomes. The Pulse Biosciences bet: pair easier acute use with a step-change in long-term outcomes.

US regulatory path and timeline

The US regulatory plan for the Pulse Biosciences nanosecond PFA is now on the clock. The company got approval to start its Investigational Device Exemption (IDE) trial at the end of 2025. It brought sites online in Q1 2026. First patient enrollment was announced in the first week of April. The trial aims to enroll up to 155 patients across up to 30 centres, mostly in the US. The FDA submission is set for 2027, with US approval targeted a year later.

LaViolette: "our official timeline to date is that we will, having started enrollment at the beginning of Q2, we plan to complete by the end of Q4."

Partnership over standalone launch

Pulse Biosciences does not plan to commercialise alone. LaViolette said: "Our go to market strategy is by way of partnership. We don't intend to commercialize as a standalone company, but through a partnership with a major player."

A partner deal would put the nanosecond PFA platform in hospitals fast and at scale. Pulse Biosciences would gain reach. A strategic partner would gain a differentiated PFA system.

The HRS 2026 readout is the data point partners and clinicians will weigh next. Coverage on Medigear.uk shows why cardiology teams must follow how Pulse Biosciences nanosecond PFA findings shape the AFib catheter market.

Source: Originating coverage based on MD+DI interview with Pulse Biosciences CEO Paul LaViolette and HRS 2026 Annual Meeting coverage from Chicago. One-year European feasibility data presented by Dr. Vivek Reddy of Mount Sinai.